SNMMI Podcast Series

SNMMI

Scintillating Conversations: Why Now is the Time to Be in Nuclear Medicine—A Podcast for SNMMI and Nuclear Medicine & Molecular Imaging Professionals

  1. Jun 8

    So You Want to Be a Medical Physicist...

    Was medical physicist an option at your school's career day? If so, lucky you! But if not, you're not alone. It's a pretty niche field, but it has a significant impact on the future of personalized medicine and treating diseases. If you're thinking that this sounds like an intriguing career path, we're joined by physicists working in several different areas of nuclear medicine: quality control, equipment calibration, and research. Ben Auer, PhD, hosts this episode as we learn more about how our guests discovered their career in medical physics, the qualifications needed, and the various opportunities that come with this highly rewarding field. Tune in now! This episode of the Podcast is sponsored by GE HealthCare. Vizamyl Important Safety Information PRODUCT INDICATIONS AND USE VIZAMYL™(flutemetamol F 18 injection) is indicated for positron-emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: Evaluation of Alzheimer's disease(AD) and other causes of cognitive declineSelection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing of information of the therapeutic products.CONTRAINDICATIONS VIZAMYL is contraindicated in patients with a history of hypersensitivity reaction to VIZAMYL or polysorbate 80. ADVERSE REACTIONS The most commonly reported adverse reactions in clinical trials were flushing(2%), increased blood pressure(2%), headache nausea and dizziness(1%). Postmarketing experience included anaphylactic reactions. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Prior to VIZAMYL administration, please read the full Prescribing Information for additional Important Safety Information: https://gehealthcare.com/vizamyl-pi  Want more SNMMI content? Follow us on: YouTube | Instagram | LinkedIn | Twitter/X

    46 min
  2. Apr 6

    AI: All Hype, A Source of Hope, or Cause for Hesitation?

    This year, 125.6 million people tuned in to watch the Seahawks face the Patriots in the Super Bowl. While the game was the main draw, it's perhaps the one time of year that commercials generate equal excitement. 2026 was no exception, but before the first quarter ended, it was clear which industry dominated the 2026 ad buys: artificial intelligence. AI has become ubiquitous in daily life, and there's almost no industry that hasn't been impacted by its adoption, including nuclear medicine. While some of its applications are clear, questions remain about how AI will be used in clinical settings, patient interactions, image interpretation, and more. On this episode of the SNMMI Podcast, Lance Burrell moderates a discussion with Dmitry Beyer, MPA, CNMT, and Samantha Heasty on AI and its capabilities, potential, and shortcomings. Tune in now! This episode of the SNMMI Podcast is sponsored by GE Healthcare. Important Safety Information – VIZAMYL PRODUCT INDICATIONS AND USE VIZAMYL™ (flutemetamol F 18 injection) is indicated for positron-emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: · Evaluation of Alzheimer’s disease (AD) and other causes of cognitive decline · Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing of information of the therapeutic products. CONTRAINDICATIONS VIZAMYL is contraindicated in patients with a history of hypersensitivity reaction to VIZAMYL or polysorbate 80. ADVERSE REACTIONS The most commonly reported adverse reactions in clinical trials were flushing (2 %), increased blood pressure (2 %), headache (1 %), nausea and dizziness (1 %). Postmarketing experience included anaphylactic reactions. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Prior to VIZAMYL administration, please read the full Prescribing Information for additional Important Safety Information: https://gehealthcare.com/vizamyl-pi Want more SNMMI content? Follow us on: YouTube | Instagram | LinkedIn | Twitter/X

    33 min
  3. Feb 17

    The SNMMI Podcast: A Heart-to-Heart on Women’s Cardiac Health

    So much of what we know about heart health is based on male models. Classic heart attack symptoms describe the experiences of men, drugs were developed largely by men for men—even in research, mouse models were male. But in recent years, our understanding of women's cardiac health has expanded, and critically, we have learned that we cannot simply apply male models to female patients. As one of our guests says, "women are not small men." For American Heart Month, join us for a heart-to-heart with members of the SNMMI Cardiovascular Council as they discuss how nuclear cardiology is providing new insight into women's heart health. Listen here or wherever you stream your podcasts.  This episode of the SNMMI Podcast is sponsored by GE Healthcare. Important Safety Information – VIZAMYL PRODUCT INDICATIONS AND USE VIZAMYL™ (flutemetamol F 18 injection) is indicated for positron-emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: · Evaluation of Alzheimer’s disease (AD) and other causes of cognitive decline · Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing of information of the therapeutic products. CONTRAINDICATIONS VIZAMYL is contraindicated in patients with a history of hypersensitivity reaction to VIZAMYL or polysorbate 80. ADVERSE REACTIONS The most commonly reported adverse reactions in clinical trials were flushing (2 %), increased blood pressure (2 %), headache (1 %), nausea and dizziness (1 %). Postmarketing experience included anaphylactic reactions. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Prior to VIZAMYL administration, please read the full Prescribing Information for additional Important Safety Information: https://gehealthcare.com/vizamyl-pi Want more SNMMI content? Follow us on: YouTube | Instagram | LinkedIn | Twitter/X

    26 min

Ratings & Reviews

5
out of 5
7 Ratings

About

Scintillating Conversations: Why Now is the Time to Be in Nuclear Medicine—A Podcast for SNMMI and Nuclear Medicine & Molecular Imaging Professionals

You Might Also Like